Literature DB >> 2154435

In-vitro activity of azithromycin compared with other macrolides and oral antibiotics against Salmonella typhi.

B Metchock1.   

Abstract

The in-vitro activity of azithromycin against 60 clinical isolates of Salmonella typhi was determined by broth microdilution and compared with eight macrolides, including erythromycin, and with other orally administered antimicrobial agents (ampicillin, amoxycillin, cefaclor, trimethoprim/sulphamethoxazole, chloramphenicol, tetracycline, and ciprofloxacin). Azithromycin was more potent (MIC range 4-16 mg/l; MIC90 8 mg/l) than erythromycin (MIC range 32- greater than 128 mg/l; MIC90 greater than 128 mg/l). Of the other macrolides, only rosaramicin showed increased activity against Salm. typhi (MIC range 16-32 mg/l; MIC90 32mg/l) when compared with erythromycin. All 60 Salm. typhi were susceptible to ciprofloxacin (MIC greater than 0.5 mg/l). In 22 isolates, resistance to one or more of the following compounds occurred: ampicillin, amoxycillin, cefaclor, tetracycline, chloramphenicol, trimethoprim/sulphamethoxazole.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154435     DOI: 10.1093/jac/25.suppl_a.29

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

2.  A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever.

Authors:  N T Chinh; C M Parry; N T Ly; H D Ha; M X Thong; T S Diep; J Wain; N J White; J J Farrar
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

3.  Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance.

Authors:  N I Girgis; T Butler; R W Frenck; Y Sultan; F M Brown; D Tribble; R Khakhria
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 4.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 5.  WITHDRAWN: Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever).

Authors:  Emmanuel E Effa; Hasifa Bukirwa
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

6.  In vitro activity of azithromycin against bacterial enteric pathogens.

Authors:  M E Gordillo; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 7.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

8.  Intracellular activity of azithromycin against bacterial enteric pathogens.

Authors:  R M Rakita; K Jacques-Palaz; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Evaluation of Antimicrobial Susceptibility Profile in Salmonella Typhi and Salmonella Paratyphi A: Presenting the Current Scenario in India and Strategy for Future Management.

Authors:  Balaji Veeraraghavan; Agila K Pragasam; Pallab Ray; Arti Kapil; Savitha Nagaraj; Sulochana Putli Bai Perumal; Karnika Saigal; Maria Thomas; Madhu Gupta; Temsunaro Rongsen-Chandola; Dasaratha Ramaiah Jinka; Jayanthi Shastri; Anna P Alexander; Roshine Mary Koshy; Anuradha De; Ashita Singh; Sheena Evelyn Ebenezer; Shanta Dutta; Ashish Bavdekar; Deepak More; Sonali Sanghavi; Raghuprakash Reddy Nayakanti; Jobin J Jacob; Anushree Amladi; Shalini Anandan; Baby S Abirami; Yamuna D Bakthavatchalam; Dhiviya P M Sethuvel; Jacob John; Gagandeep Kang
Journal:  J Infect Dis       Date:  2021-11-23       Impact factor: 5.226

10.  Salmonella subtypes with increased MICs for azithromycin in travelers returned to The Netherlands.

Authors:  Robert-Jan Hassing; Wil H F Goessens; Wilfrid van Pelt; Dik J Mevius; Bruno H Stricker; Nicky Molhoek; Annelies Verbon; Perry J J van Genderen
Journal:  Emerg Infect Dis       Date:  2014-04       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.